TJ301 Protocol No.: CTJ301UC201 Date: 16 May 2017

Solution for Injection Ver.1.1
Clinical Trial Protocol Supersedes: Ver.1.0
Page 1 of 97

CLINICAL TRIAL PROTOCOL

A Phase IT, Randomized, Double-blind, Placebo-controlled Study to Evaluate
the Safety and Efficacy of TJ301 (FE 999301) Administered Intravenously in
Patients with Active Ulcerative Colitis

Protocol Number: CTJ301UC201

Investigational Medicinal Product: |= TJ301 (solution for injection), also referred to as FE
999301 and Olamkicept

Indication: Active Ulcerative Colitis
Phase: 2
Investigators: Multicenter, international, across Mainland China,

Taiwan, Republic of Korea and Australia

Coordinating Investigator Prof. Dr. Minhu Chen
Chair, Department of Gastroenterology and Hepatology
Vice President
The First Affiliated Hospital, Sun Yat-sen University
58 Zhongshan Road, Guangzhou, China

Expert committee Prof. Dr. Stefan Schreiber
Institute for Clinical Molecular Biology University Hospital
Schleswig-Holstein
Schittenhelmstrasse 12, 24105 Kiel, Germany

Name and Address of Sponsor: Leading Biopharm Limited
Sponsor Contact:
Yin Liu
Suite 802, OmniVision Park West Tower
88 Shangke Road, Pudong, Shanghai 201210, China
Tel: + 86 135 0178 1723

GCP Statement: This trial will be performed in compliance with GCP.
The information in this document is confidential and is proprietary to Leading Biopharm Limited. It is understood that

information in this document shall not be disclosed to any third party, in any form, without prior written consent of an
authorised officer of Leading Biopharm Limited.

Leading Biopharm Limited CONFIDENTIAL